Literature DB >> 17587138

RAGE activation by S100P in colon cancer stimulates growth, migration, and cell signaling pathways.

Maren K Fuentes1, Shraddha S Nigavekar, Thiruvengadam Arumugam, Craig D Logsdon, Ann Marie Schmidt, Juliet C Park, Emina H Huang.   

Abstract

PURPOSE: Colon cancer is the third most prevalent cancer in the United States. However, the molecular mechanisms involved in the development and progression of colon cancer are incompletely understood. This study was initiated to explore the potential role of the receptor for advanced glycation end-products and S100P in modulation of key properties of human colon cancer cells.
METHODS: Western blot, reverse transcription-polymerase chain reaction, and quantitative polymerase chain reaction were performed for detection of the receptor for advanced glycation end-products and S100P in colon cancer and matched normal colon. The influence of exogenously added S100P was analyzed on SW480 colon cancer cell line proliferation, migration, phosphorylation of mitogen activated protein kinases, and NFkappaB activation. To identify the mechanisms involved in these responses, coimmunoprecipitation examining the S100P/Receptor for advanced glycation end-products interaction and the effects of receptor for advanced glycation end-products inhibition in this interaction were analyzed.
RESULTS: Although the receptor for advanced glycation end-products was present in normal and malignant colon specimens, only the malignant specimens expressed S100P. Treatment of SW480 cells with S100P increased proliferation and cell migration. Addition of exogenous S100P stimulated both ERK1/2 phosphorylation and NFkappaB activity. The interaction between S100P and the receptor for advanced glycation end-products was demonstrated by coimmunoprecipitation of these molecules from SW480 cells. Antagonism of the receptor for advanced glycation end-products blocked this interaction and the biologic effects of S100P on these cells.
CONCLUSIONS: These data indicate that S100P is expressed at greater levels in colon cancer than matched normal tissue and that S100P stimulates colon cancer cell growth, migration, Erk phosphorylation, and NFkappaB activation in vitro, suggesting that this ligand/receptor pair may be targeted for the development of new therapies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17587138     DOI: 10.1007/s10350-006-0850-5

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  63 in total

1.  S100P dissociates myosin IIA filaments and focal adhesion sites to reduce cell adhesion and enhance cell migration.

Authors:  Min Du; Guozheng Wang; Thamir M Ismail; Stephane Gross; David G Fernig; Roger Barraclough; Philip S Rudland
Journal:  J Biol Chem       Date:  2012-03-06       Impact factor: 5.157

Review 2.  S100P: a novel therapeutic target for cancer.

Authors:  Thiruvengadam Arumugam; Craig D Logsdon
Journal:  Amino Acids       Date:  2010-05-28       Impact factor: 3.520

3.  Proteomic signatures of acquired letrozole resistance in breast cancer: suppressed estrogen signaling and increased cell motility and invasiveness.

Authors:  Syreeta L Tilghman; Ian Townley; Qiu Zhong; Patrick P Carriere; Jin Zou; Shawn D Llopis; Lynez C Preyan; Christopher C Williams; Elena Skripnikova; Melyssa R Bratton; Qiang Zhang; Guangdi Wang
Journal:  Mol Cell Proteomics       Date:  2013-05-23       Impact factor: 5.911

Review 4.  Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer.

Authors:  Geetha Srikrishna; Hudson H Freeze
Journal:  Neoplasia       Date:  2009-07       Impact factor: 5.715

5.  Expression of the receptor for advanced glycation end-products and frequency of polymorphism in lung cancer.

Authors:  Hongmei Wang; Yongchun Li; Wencheng Yu; Liqing Ma; Xia Ji; Wei Xiao
Journal:  Oncol Lett       Date:  2015-05-12       Impact factor: 2.967

6.  Green tea catechin extract in intervention of chronic breast cell carcinogenesis induced by environmental carcinogens.

Authors:  Kusum Rathore; Hwa-Chain Robert Wang
Journal:  Mol Carcinog       Date:  2011-08-31       Impact factor: 4.784

7.  Increased expression of S100A6 promotes cell proliferation and migration in human hepatocellular carcinoma.

Authors:  Ziqiang Li; Mei Tang; Bo Ling; Shiying Liu; Yu Zheng; Chunlai Nie; Zhu Yuan; Liangxue Zhou; Gang Guo; Aiping Tong; Yuquan Wei
Journal:  J Mol Med (Berl)       Date:  2013-11-27       Impact factor: 4.599

8.  In vitro anticancer effects of a RAGE inhibitor discovered using a structure-based drug design system.

Authors:  Ali Hafez Ali Mohammed El-Far; Seiichi Munesue; Ai Harashima; Akira Sato; Mika Shindo; Shingo Nakajima; Mana Inada; Mariko Tanaka; Akihiko Takeuchi; Hiroyuki Tsuchiya; Hiroshi Yamamoto; Hazem M E Shaheen; Yasser S El-Sayed; Shuhei Kawano; Sei-Ichi Tanuma; Yasuhiko Yamamoto
Journal:  Oncol Lett       Date:  2018-01-29       Impact factor: 2.967

Review 9.  Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response.

Authors:  Shi Fang Yan; Ravichandran Ramasamy; Ann Marie Schmidt
Journal:  J Mol Med (Berl)       Date:  2009-02-03       Impact factor: 4.599

10.  Receptor for advanced glycation end products: its role in Alzheimer's disease and other neurological diseases.

Authors:  Lih-Fen Lue; Douglas Gordon Walker; Sandra Jacobson; Marwan Sabbagh
Journal:  Future Neurol       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.